Back to search results
NCT05872022

A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy

Enrolling by Invitation
Not specifiedAges 15–50Observational
Novo Nordisk A/S
~728 participants
Updated 2026-01-14 on ClinicalTrials.gov
What's tested:No Intervention

At a glance

Recruiting sites
0 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Infants with Major Congenital Malformation (MCM)
Measured over From date of conception (DOC) to pregnancy outcome for foetal losses or 12 months of infant age for live births

Conditions

Pregnancy
Obesity
Overweight

Explore related trials

ObesityOverweightPregnancy

Where it's being run

3 sites across 3 states
New Jersey1
Spain1
United Kingdom1

Study leadership

  • Clinical Transparency (dept. 2834). · STUDY_DIRECTOR · Novo Nordisk A/S

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Signed consent obtained before any study-related activities
Female 15-50 years of age at the time of signing consent
Currently or recently pregnant
Resident of country included in the study
Authorisation for her HCP(s) to provide data to the registry
Exposed to Wegovy cohort: Exposure to at least one dose of Wegovy at any time during pregnancy for the treatment of obesity or overweight with at least one weight-related comorbid condition.
Unexposed to Wegovy cohort: Have obesity or overweight with at least one weight related comorbid condition at conception

Exclusion

Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation
Unexposed to Wegovy cohort: Exposure to Wegovy or other GLP-1 RA at any time during pregnancy

What this trial measures

  • Number of Infants with Major Congenital Malformation (MCM)From date of conception (DOC) to pregnancy outcome for foetal losses or 12 months of infant age for live births

    Number of infants with MCM is defined as an abnormality of body structure or function that is present at birth; is of prenatal origin (that is, birth defect); has significant medical, social, or cosmetic consequences for the affected individual; and typically requires medical intervention.